Depomed settles with generics over Gralise dispute

Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.

The settlements with Incepta and Zydus allow the companies to start selling gabapentin tablets on January 1, 2024.

Gralise is used to treat pain after having shingles. Sales of the product totalled $36 million in 2013.

Depomed filed patent infringement cases against Actavis, Incepta and Zydus at the US District Court for the District of New Jersey in 2012, after the generic drug makers filed Abbreviated New Drug Applications with the US Food and Drug Administration to market generic versions of Gralise.

Depomed’s litigation with Actavis is still pending.